STOCK TITAN

C4 Therapeutics: Squadron reports 7.9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

C4 Therapeutics, Inc. (CCCC) is the subject of an amended ownership report in which Squadron Master Fund LP, its investment adviser Squadron Capital Management LLC, and partners Matthew Sesterhenn and William Blank each report shared beneficial ownership of 9,718,683 shares, or 7.9% of the class. The reported amount comprises 9,318,683 common shares and 400,000 shares underlying currently exercisable long call options held by Squadron Capital Management LLC.

The report gives September 30, 2026 as the event date. Its percentage calculation uses 123,025,136 shares outstanding as of July 31, 2026, plus the 400,000 option shares. The Fund has the right to receive or direct receipt of dividends and sale proceeds; Squadron Capital Management, Sesterhenn and Blank disclaim beneficial ownership.

Shared beneficial ownership 9,718,683 shares Amount reported by each of the four reporting persons.
Common shares 9,318,683 shares Component of the reported beneficial ownership amount.
Shares underlying long call options 400,000 shares Options are currently exercisable and held by Squadron Capital Management LLC.
Ownership percentage 7.9% Reported percentage of C4 Therapeutics common stock.
Shares outstanding 123,025,136 shares As of July 31, 2026; used in the ownership percentage calculation along with 400,000 option shares.
beneficial ownership regulatory
"may be deemed to be the beneficial owner"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 9,718,683.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 9,718,683.00"
long call options financial
"400,000 shares of Common Stock underlying long call options"
Investment Advisers Act of 1940 regulatory
"registered under the Investment Advisers Act of 1940"
A U.S. federal law that sets rules for people and firms who give investment advice, requiring them to register with regulators, be honest about conflicts, keep records, and follow basic standards of care. It matters to investors because those rules act like licensing and consumer protections — similar to having safety standards for a mechanic — helping ensure advisers act in clients’ financial interests and reducing the risk of fraud or misuse of funds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did the reporting persons report owning in CCCC?

Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank each reported shared beneficial ownership of 9,718,683 C4 Therapeutics shares, equal to 7.9% of the class. The amount includes 9,318,683 common shares and 400,000 shares underlying currently exercisable long call options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





12529R107

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:11/16/2026
Squadron Capital Management LLC
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner
Date:11/16/2026
Matthew Sesterhenn
Signature:/s/ Matthew Sesterhenn
Name/Title:Matthew Sesterhenn
Date:11/16/2026
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:11/16/2026

Keep reading